This is the authors' abstract. We don't add key points for this paper.
In hospitalized mild to moderate COVID-19 Patients with pre-existing Type 2 diabetes, we evaluated the efficacy of add-on customized Ayurveda intervention as compared to Standard of Care (SOC) in ameliorating symptoms, ICU admission and Ventilator support plus IL6 and CRP over 15 days. In this quasi-experimental trial, 24 participants per arm diagnosed with COVID-19 by RT-PCR, aged 18-75 years, fulfilling the inclusion/exclusion criteria were inducted. The subjects were allocated, depending on their own voluntary choice to SOC plus Ayurveda (group 1) or SOC alone (group 2) for 15 days. The analyses used the Cochran-Mantel-Haenszel test, Multivariate ANOVA plus within group Repeated Measures ANOVA and Cochran’s Q test. Of the 13 symptoms, cough (p = 0.04), general weakness (p = 0.02), and sore throat (p = 0.02) were statistically significantly different across the groups, with Group I(add-on) improving better than Group II(SOC). IL-6 dropped rapidly in Group1 by 7 days (p=0.006) Group 2 caught up by day 15.(p=0.001). CRP improved slower than IL-6. The time to maximum change wasn’t statistically different for IL-6 and CRP between the groups at day 15. There were no differences in Random Blood Sugar and AEs to Ayurveda added SOC group. In this exploratory pilot study, cough, weakness and sore throat improved more in the add-on Ayurveda than in the SOC. IL-6 concentrations declining more rapidly in the add-on Ayurveda. Clinical and laboratory AEs suggested no additional toxicity of add-on Ayurveda treatments. This study supports the need for a randomized, double-blind trial.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: